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 Childhood cancer survivors often develop subsequent neoplasms secondary to radio- (RT) or chemotherapy (CHT). Risk 
factors for the secondary tumors are the female gender, older age at diagnosis, Hodgkin’s lymphoma treatment and the 
use of RT. The cumulative incidence of the second malignant neoplasm, excluding non-melanoma skin cancer, 30 years 
after the childhood cancer diagnosis is around 8% [1]. We present the case of a patient who developed three independent 
malignancies following radical treatment of nephroblastoma (Wilms’ tumor; WT) in childhood, found at the age of 53 to 
be a carrier of the 657_661delACAAA (p. Lys219fs) mutation in the 6/16 exon of the nibrin coding gene (NBN).
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Case report
A 52-year-old woman was diagnosed with hepatic hilum lym-
phadenopathy in November 2016. Past medical history of 
the patient included two metachronic neoplasms: WT with 
peritoneal infiltration at the age of six years treated with left 
nephrectomy followed by CHT with actinomycin D and left 
flank RT at the dose of 35.2 Gy, and grade III adenocarcinoma 
of the descending colon treated with left hemicolectomy 
at the age of 26 years. The family history was unremarkable.
At admission, physical examination was unremarkable. 
The patient’s performance status ECOG was 0. Magnetic re-
sonance imaging (MR of 08.2016) showed the presence of 
a very small (11 x 13 mm) lymph node with low radiotracer 
uptake (SUV 2.1) at the positron emission tomography scan 
with 18-fluorodeoxyglucose. Six months later, MR showed 
a significant progression of the lesion (35 x 22 mm). The ul-
trasound-guided core-needle biopsy proved the diagnosis of 
a grade II leiomyosarcoma. In April 2017, the tumor originating 
from vena cava inferior was removed. Despite the presence of 
tumor cells in the resection margin adjuvant treatment was 
not administered due to the hemorrhagic complications and 
prolonged postoperative recovery. Eight months later, the 
patient was diagnosed with undifferentiated ovarian cancer, 
stage IA, and treated with radical surgery followed by 6 cycles 
of adjuvant CHT (carboplatin and paclitaxel).
Genetic testing after the diagnosis of sarcoma showed that 
the patient was a carrier of the 657_661delACAAA (p. Lys219fs) 
mutation in the 6/16 exon of the nibrin coding gene (NBN), 
uncommon in the Polish population. The leiomyosarcoma 
specimen examined for the presence of potentially targetable 
mutations using Archer FusionPlex CTL panel (ArcherDX) did 
not yield any hits.
Discussion
Each year about 1000 children in Poland are diagnosed with 
cancer [2], including about 60 cases of the most common 
kidney tumor – WT [3]. Multimodal therapy including surgery 
with perioperative CHT and adjuvant RT in high-risk tumors 
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results in 90% 5-year overall survival in localized disease and 
75% at the metastatic stage [4].
However, children who underwent RT or CHT are at signi-
ficantly higher risk of subsequent neoplasms compared to the 
general population [1, 5, 6]. To decrease the risk of secondary 
malignancies RT, it is recommended only for high-risk groups, 
with low total doses and minimal exposure of adjacent organs. 
In consequence, the incidence rates of secondary malignancies 
in the subsequent decades have decreased, yet the risk is still 
higher than in the general population [5].
The cumulative incidence of a secondary malignancy in 
WT survivors is 0.6% at 10 years, 1.6% at 20 years and 3.8% 
at 30 years after the initial diagnosis [6]. The most common 
secondary malignancies include colon cancer (SIR 14.1 95% 
CI 1.7–51.1), soft tissue sarcoma (SIR 11.4 95% CI 2.4–33.4), 
liver cancer (SIR 34.7 95% CI 4.2–125.5) and thyroid cancer 
(SIR 4.4 95% CI 1.2–11.3) [6]. Overall survival for patients with 
subsequent malignancies is 64.5% at 5 years [6].
In the presented case, the development of the left-sided 
colon cancer 20 years after initial diagnosis of WT was typical, 
although the age of 26 years at diagnosis is much below the 
median age of colon cancer occurrence [2, 5, 6]. Long-term 
follow-up showed that the surgical resection was curative. 
However, 45 years after WT treatment the patient developed 
another neoplasm – leiomyosarcoma of the inferior vena cava. 
Vascular leiomyosarcomas account for about 2% of adult soft 
tissue sarcomas, most frequently in 50-60-year-old women 
[7]. The most common location is inferior vena cava. About 
400 cases have been reported in the literature to date, none 
of which was secondary to the childhood cancer therapy. 
Due to the rarity of the disease, an optimal treatment has not 
been established [7]. 
The presented patient did not receive any adjuvant treat-
ment because of serious postoperative complications. Ovarian 
cancer diagnosed shortly afterwards as the third subsequent 
malignancy was typical, regarding the latency period, for radia-
tion-induced solid tumors [5, 6]. This malignancy was treated 
with standard surgery followed by adjuvant CHT.
Our case is interesting for several reasons. First, despite 
an increased risk of subsequent neoplasms, childhood can-
cer survivors seldom develop multiple malignant tumors 
diagnosed at early stages that can be successfully managed 
with surgery. Second, the patient was carrying a pathogenic 
mutation of the NBN gene. Physiologically, the nibrin protein 
is important in the process of the double-strand breaks DNA 
repair. The biallelic defects are responsible for the Nijmegen 
syndrome [8]. Our patient did not present the full spectrum of 
Nijmegen syndrome features, but multiple malignancies after 
radiotherapy in childhood are probably connected with the 
carried mutation. Heterozygotes for NBN mutation are also at 
increased risk of malignancies [9]. All of the 127 variants of the 
NBN gene are pathogenic. Finally, it is difficult to define the 
role of the NBN mutation in the development of subsequent 
malignancies versus the radio- and chemotherapy in childho-
od and frequent CT examinations. Recent epidemiological 
results suggested an increased cancer risk after receiving CT 
examinations in childhood or adolescence. The carcinogenic 
role of this factor is unclear due to the possible impact of other 
cancer predisposing factors. Nonetheless, an Australian study, 
with a mean follow-up of 9.5 years, reported excess risks of 
cancer at several sites, and an increase of about 20% in the 
risk of all cancers, compared with individuals not exposed to 
CT examination [10]. 
Conclusion
The presented case exemplifies the importance of genetic 
counseling in childhood cancer survivors who have not been 
genetically tested. Wise and watchful follow-up in childhood 
cancer survivors allows for early diagnosis.
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